ADONA ® is a sodium carbazocrome sulfonate drug.
THERAPEUTIC GROUP: Antihemorrhagic - Hemostatic.
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications ADONA ® Carbazocromo sulfonato sodium
ADONA ® is used in the prevention and treatment of bleeding associated with states of capillary fragility.
Mechanism of action ADONA ® Carbazocromo sulfonato sodium
Carbazocromo sodium sulfonate, taken orally via ADONA ® is absorbed at gastro-intestinal level, reaching maximum plasma concentrations approximately 2 hours after intake.
Pharmacokinetic studies with the radiolabelled active principle have shown that carbazocromo can be rapidly distributed throughout the body, with the exception of the nervous system, concentrating mainly on renal, cutaneous, connective and cardiac levels.
Unlike other anti-haemorrhagic drugs, which essentially act on the coagulation and thrombotic abilities of the blood, carbazocromo - although it does not interfere with these mechanisms - is able to reduce both the frequency and the bleeding time.
The action underlying its therapeutic effect seems to be associated with the ability to normalize vascular structures, increasing their resistance and reducing their permeability.
These characteristics make ADONA ® a drug particularly indicated for the treatment of vascular fragility and associated symptoms.
Studies carried out and clinical efficacy
CARBAZOCROME IN THE TREATMENT OF HEMORROIDARY DISEASE
The haemorrhoidal disease is a pathological condition characterized by inflammation, and in some cases by prolapses and bleeding, of the haemorrhoidal plexus veins. This decidedly annoying disease can be effectively controlled by the administration of vasoprotectors such as carbazocromo and troxerutina.
2. THE INFFICACY OF THE CARBAZOCROME IN PREVENTING THE SHOCK IN THE DENGUE
Dengue is a viral disease transmitted by flaviviridae, with a particularly inauspicious clinical course. In addition to the common febrile reaction, it is possible to describe a hemorrhagic reaction characterized by the production of inflammatory cytokines, responsible for the increase in vascular permeability and vascular fragility underlying the shock. Several research groups thought that the biological effects of carbazocromo could improve the course of the disease, preventing shock, but unfortunately the double-blind experimentation did not lead to the expected results.
3. MOLECULAR MECHANISM OF THE CARBAZOCROME
The vasoprotective efficacy of carbazocromo has been tested on cell cultures of aortic endothelium subjected to tryptase stress, thrombin, bradykinin and high pro inflammatory agents. The active ingredient in question has proved to be particularly effective in preserving the structure of the endothelium, reducing its permeability and regulating the action of some enzymes involved in the intracellular signal transmission process.
Method of use and dosage
ADONA ® 25 mg carbazocromo sulfonato sodium tablets or 50 mg oral solution powder: the dosage formulation must be evaluated by the physician taking into account the physiopathological condition, the severity of the pathology and the therapeutic goals of the patient.
It is therefore important to consult your doctor.
IN ANY CASE, BEFORE TAKING ADONA ® Carbazocromo sulfonato sodium - THE REQUIREMENT AND CHECK OF YOUR DOCTOR IS NECESSARY.
Warnings ADONA ® Carbazocromo sulfonato sodium
ADONA ® should be administered under strict medical supervision.
The drug should be withdrawn in the event of a skin rash, hives or any other sign of sensitization to the active ingredient or any of its components.
ADONA ® does not seem to alter the patient's perceptive abilities, not influencing the normal ability to drive vehicles or use machinery.
PREGNANCY AND BREASTFEEDING
The absence of studies on the safety and efficacy of sodium carbazocromo sulfonato on the health of the fetus does not allow to evaluate the safety profile of the drug when taken during pregnancy. Therefore, it is not recommended for use during the period of pregnancy or during the subsequent period of breastfeeding.
Interactions
At present, the various pharmacokinetic studies have shown no potentially dangerous interactions with other active ingredients.
Contraindications ADONA ® Carbazocromo sulfonato sodium
ADONA ® must not be administered in case of ascertained hypersensitivity to the active ingredient or to one of its excipients.
Undesirable effects - Side effects
ADONA ® appears to be well tolerated by various patients, with the presence of mild and transient side effects such as gastro-intestinal disorders and loss of appetite.
However, it is possible, following the intake of ADONA ® the appearance of obvious signs of sensitization, such as skin rash, hives and photosensitivity, which suggest the immediate suspension of the drug.
Note
ADONA ® is available only under medical prescription.
